HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
Pharmacologic Treatments for COVID-19
During corona virus, the FDA has issued an emergency use authorization (EUA) for bamlanivimab, which is a monoclonal antibody given against the spike protein of SARS-CoV-2
Baricitinib or JAK inhibitor is used in combination with remdesivir, in the treatment of suspected or laboratory-confirmed coronavirus disease in hospitalized patients aged 2 years and elderly who require supplemental oxygen, invasive mechanical ventilation. Various other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as possible therapies.
Committee Members
Saad Tayyab
UCSI University, Malaysia
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Marino Nebuloni
University of Insubria, Italy PDDS 2025 Speakers
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Marino Nebuloni
University of Insubria, Italy
Saad Tayyab
UCSI University, MalaysiaSubmit your abstract Today
Title : Medical liver Biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Macitentan/Tadalafil Combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia